Related Experiment Video
Updated: Jun 26, 2026
The Nematode Caenorhabditis Elegans - A Versatile In Vivo Model to Study Host-microbe Interactions
Published on: October 18, 2017
A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds
Emmanouil Tampakakis1, Ikechukwu Okoli, Eleftherios Mylonakis
1Division of Infectious Diseases, Massachusetts General Hospital, Gray-Jackson 504, 55 Fruit Street, Boston, Massachusetts 02114, USA.
Abstract:
Traditional antimicrobial screens focus on compounds that block the growth of microbial organisms. A new Caenorhabditis elegans-based bioassay can be used for the identification of antifungal compounds that are effective against Candida albicans. According to the protocol, adult nematodes are infected with C. albicans and moved to 96-well plates containing the tested compounds. In the presence of compounds with no antifungal activity, the fungus kills the worms and develops filaments that penetrate through the cuticle. In contrast to traditional screening methods and mammalian models, this facile, time-efficient and less costly assay allows the study of Candida cells in nonplanktonic form and may allow the concurrent evaluation of toxicity and antifungal activity and identify compounds that target virulence factors or modify host immune response. The screening assay takes about 5-6 d depending on the experimental design.
Insights
A new bioassay using the nematode Caenorhabditis elegans identifies antifungal compounds against Candida albicans. This efficient method studies fungal growth and potential drug toxicity, offering a faster, cost-effective alternative.
Area of Science:
- Microbiology
- Parasitology
- Drug Discovery
Background:
- Traditional antimicrobial screening methods primarily target microbial growth inhibition.
- Developing effective antifungal compounds against Candida albicans remains a significant challenge.
- Existing models for antifungal screening can be time-consuming, costly, and may not fully represent in vivo conditions.
Purpose of the Study:
- To introduce and validate a novel Caenorhabditis elegans-based bioassay for identifying antifungal compounds.
- To enable the study of Candida albicans in a nonplanktonic, filamentous form.
- To facilitate the concurrent evaluation of antifungal activity, compound toxicity, and potential modulation of host-pathogen interactions.
Main Methods:
- Infection of adult Caenorhabditis elegans (nematodes) with Candida albicans.
- Exposure of infected nematodes to various test compounds in a 96-well plate format.
- Observation of nematode survival and fungal filamentation as indicators of antifungal activity and compound efficacy.
Main Results:
- The assay effectively distinguishes between compounds with and without antifungal activity against C. albicans.
- Fungal filamentation and cuticle penetration in nematodes indicate a lack of effective antifungal action.
- The assay provides a facile, time-efficient, and less costly method compared to traditional screens and mammalian models.
Conclusions:
- The Caenorhabditis elegans bioassay is a promising tool for antifungal drug discovery, particularly for Candida albicans.
- This model allows for the study of fungal virulence factors and host-pathogen interactions in a relevant context.
- The assay's efficiency and cost-effectiveness support its potential for high-throughput screening and concurrent toxicity assessments.
